Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ananth Ravi

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
JAMA Network Open|February 25, 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate CancerCristian Udovicich, Patrick Cheung, William Chu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapyYasir Alayed, Melanie Davidson, Harvey Quon, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
European Urology Oncology|April 27, 2025
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body RadiotherapyWee Loon Ong, Harvey Quon, Aldrich Ong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
JAMA Network Open|February 25, 2026
SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate CancerCristian Udovicich, Patrick Cheung, William Chu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapyYasir Alayed, Melanie Davidson, Harvey Quon, et al.
Pageof 9